Eukles Asset Management Invests $1.62 Million in Illumina, Inc. (NASDAQ:ILMN)

Eukles Asset Management bought a new position in shares of Illumina, Inc. (NASDAQ:ILMN) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 4,403 shares of the life sciences company’s stock, valued at approximately $1,621,000.

Several other institutional investors also recently modified their holdings of ILMN. Jennison Associates LLC raised its position in shares of Illumina by 3.7% during the 1st quarter. Jennison Associates LLC now owns 5,679,678 shares of the life sciences company’s stock valued at $1,764,619,000 after buying an additional 200,114 shares during the period. Geode Capital Management LLC raised its position in shares of Illumina by 10.1% during the 4th quarter. Geode Capital Management LLC now owns 1,854,346 shares of the life sciences company’s stock valued at $555,173,000 after buying an additional 170,046 shares during the period. Northern Trust Corp raised its position in shares of Illumina by 0.9% during the 1st quarter. Northern Trust Corp now owns 1,660,761 shares of the life sciences company’s stock valued at $515,981,000 after buying an additional 14,669 shares during the period. Thoroughbred Financial Services LLC raised its position in shares of Illumina by 38,516.8% during the 2nd quarter. Thoroughbred Financial Services LLC now owns 875,828 shares of the life sciences company’s stock valued at $87,583,000 after buying an additional 873,560 shares during the period. Finally, American Century Companies Inc. raised its position in shares of Illumina by 107.1% during the 1st quarter. American Century Companies Inc. now owns 815,875 shares of the life sciences company’s stock valued at $253,484,000 after buying an additional 421,953 shares during the period. Institutional investors and hedge funds own 90.95% of the company’s stock.

In other news, Director Jay T. Flatley sold 3,300 shares of the company’s stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $304.44, for a total transaction of $1,004,652.00. Following the sale, the director now owns 282,516 shares of the company’s stock, valued at $86,009,171.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Robert P. Ragusa sold 2,230 shares of the company’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $293.09, for a total value of $653,590.70. Following the sale, the senior vice president now directly owns 10,685 shares in the company, valued at approximately $3,131,666.65. The disclosure for this sale can be found here. In the last three months, insiders sold 50,458 shares of company stock worth $16,527,618. 0.38% of the stock is owned by corporate insiders.



NASDAQ ILMN traded down $0.16 on Thursday, reaching $284.91. The stock had a trading volume of 32,955 shares, compared to its average volume of 1,242,876. The company has a market capitalization of $41.98 billion, a price-to-earnings ratio of 49.77, a price-to-earnings-growth ratio of 2.71 and a beta of 1.10. The company has a quick ratio of 6.10, a current ratio of 6.79 and a debt-to-equity ratio of 0.42. Illumina, Inc. has a 12-month low of $268.62 and a 12-month high of $380.76. The company’s fifty day moving average price is $321.15.

Illumina (NASDAQ:ILMN) last announced its earnings results on Monday, July 29th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.32 by $0.03. The company had revenue of $838.00 million for the quarter, compared to analyst estimates of $835.12 million. Illumina had a return on equity of 21.73% and a net margin of 27.56%. The firm’s quarterly revenue was up 1.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.43 earnings per share. On average, sell-side analysts expect that Illumina, Inc. will post 6.04 earnings per share for the current year.

Several analysts have recently commented on the stock. Credit Suisse Group reaffirmed a “buy” rating and set a $340.00 price target on shares of Illumina in a research report on Wednesday, July 31st. BidaskClub lowered shares of Illumina from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 13th. Bank of America lowered shares of Illumina from a “buy” rating to an “underperform” rating and set a $310.00 price target on the stock. in a research report on Friday, July 12th. ValuEngine raised shares of Illumina from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Finally, Piper Jaffray Companies reduced their price target on shares of Illumina from $382.00 to $348.00 and set an “overweight” rating on the stock in a research report on Tuesday, July 30th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have issued a buy rating to the company. Illumina currently has an average rating of “Buy” and a consensus price target of $330.92.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Featured Story: After-Hours Trading

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.